Repligen Corporation Announces Agreement to Acquire Bioprocess Systems Innovator ARTeSYN Biosolutions and Completes Acquisition of Non-Metallic Solutions
Proposed A RTeSYN a cquisition adds gold standard single - use downstream bioprocessing s ystems
Advances Repligen’s S ystems strategy in Filtration and Chromatography , c omplement ing TangenX ® F lat S heet cassettes and OPUS ® PP C Completes acquisition of Non-Metallic Solutions (NMS), complementing our recent acquisition of EMT and further strengthens our single-use flow paths, durable plastics and assembly portfolio
WALTHAM, Mass., Oct. 27, 2020 (GLOBE NEWSWIRE) - Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it has entered into a definitive agreement to acquire privately-held ARTeSYN Biosolutions (“ARTeSYN”) for approximately $200 million, comprised of approximately $130 million in cash and approximately $70 million in Repligen common stock. ARTeSYN Biosolutions is projected to generate approximately $30 million in revenue (pro forma) in 2020, led by the success of its
